Fondaparinux sodium is a synthetic and specific inhibitor of activated Factor X (Xa).

Acotiamide monohydrochloride trihydrate is an orally active and first-in-class gastroprokinetic agent for the treatment of functional dyspepsia. Acotiamide monohydrochloride trihydrate enhances acetylcholine released by enteric neurons through muscarinic

For the detailed information of AS-2034178,AS 2034178, the solubility of AS-2034178,AS 2034178 in water, the solubility of AS-2034178,AS 2034178 in DMSO, the solubility of AS-2034178,AS 2034178 in PBS buffer, the animal experiment (test) of AS-2034178,AS 2034178, the cell expriment (test) of AS-2034178,AS 2034178, the in vivo, in vitro and clinical trial test of AS-2034178,AS 2034178, the EC50, IC50,and affinity,of AS-2034178,AS 2034178, For the detailed information of AS-2034178,AS 2034178, the solubility of AS-2034178,AS 2034178 in water, the solubility of AS-2034178,AS 2034178 in DMSO, the solubility of AS-2034178,AS 2034178 in PBS buffer, the animal experiment (test) of AS-2034178,AS 2034178, the cell expriment (test) of AS-2034178,AS 2034178, the in vivo, in vitro and clinical trial test of AS-2034178,AS 2034178, the EC50, IC50,and affinity,of AS-2034178,AS 2034178, Please contact DC Chemicals..

For the detailed information of BBS-4, the solubility of BBS-4 in water, the solubility of BBS-4 in DMSO, the solubility of BBS-4 in PBS buffer, the animal experiment (test) of BBS-4, the cell expriment (test) of BBS-4, the in vivo, in vitro and clinical trial test of BBS-4, the EC50, IC50,and affinity,of BBS-4, Please contact DC Chemicals..

For the detailed information of BIO-32546, the solubility of BIO-32546 in water, the solubility of BIO-32546 in DMSO, the solubility of BIO-32546 in PBS buffer, the animal experiment (test) of BIO-32546, the cell expriment (test) of BIO-32546, the in vivo, in vitro and clinical trial test of BIO-32546, the EC50, IC50,and affinity,of BIO-32546, For the detailed information of BIO-32546, the solubility of BIO-32546 in water, the solubility of BIO-32546 in DMSO, the solubility of BIO-32546 in PBS buffer, the animal experiment (test) of BIO-32546, the cell expriment (test) of BIO-32546, the in vivo, in vitro and clinical trial test of BIO-32546, the EC50, IC50,and affinity,of BIO-32546, Please contact DC Chemicals..

For the detailed information of DTP3, the solubility of DTP3 in water, the solubility of DTP3 in DMSO, the solubility of DTP3 in PBS buffer, the animal experiment (test) of DTP3, the cell expriment (test) of DTP3, the in vivo, in vitro and clinical trial test of DTP3, the EC50, IC50,and affinity,of DTP3, Please contact DC Chemicals..

For the detailed information of Epothilone F, the solubility of Epothilone F in water, the solubility of Epothilone F in DMSO, the solubility of Epothilone F in PBS buffer, the animal experiment (test) of Epothilone F, the cell expriment (test) of Epothilone F, the in vivo, in vitro and clinical trial test of Epothilone F, the EC50, IC50,and Affinity of Epothilone F, Please contact DC Chemicals..

For the detailed information of GPI-1046, the solubility of GPI-1046 in water, the solubility of GPI-1046 in DMSO, the solubility of GPI-1046 in PBS buffer, the animal experiment (test) of GPI-1046, the cell expriment (test) of GPI-1046, the in vivo, in vitro and clinical trial test of GPI-1046, the EC50, IC50,and Affinity of GPI-1046, Please contact DC Chemicals..

For the detailed information of IN00076730, the solubility of IN00076730 in water, the solubility of IN00076730 in DMSO, the solubility of IN00076730 in PBS buffer, the animal experiment (test) of IN00076730, the cell expriment (test) of IN00076730, the in vivo, in vitro and clinical trial test of IN00076730, the EC50, IC50,and affinity,of IN00076730, For the detailed information of IN00076730, the solubility of IN00076730 in water, the solubility of IN00076730 in DMSO, the solubility of IN00076730 in PBS buffer, the animal experiment (test) of IN00076730, the cell expriment (test) of IN00076730, the in vivo, in vitro and clinical trial test of IN00076730, the EC50, IC50,and affinity,of IN00076730, Please contact DC Chemicals..

For the detailed information of JNJ40411813, the solubility of JNJ40411813 in water, the solubility of JNJ40411813 in DMSO, the solubility of JNJ40411813 in PBS buffer, the animal experiment (test) of JNJ40411813, the cell expriment (test) of JNJ40411813, the in vivo, in vitro and clinical trial test of JNJ40411813, the EC50, IC50,and Affinity of JNJ40411813, Please contact DC Chemicals..

For the detailed information of KF-4317, the solubility of KF-4317 in water, the solubility of KF-4317 in DMSO, the solubility of KF-4317 in PBS buffer, the animal experiment (test) of KF-4317, the cell expriment (test) of KF-4317, the in vivo, in vitro and clinical trial test of KF-4317, the EC50, IC50,and Affinity of KF-4317, Please contact DC Chemicals..

For the detailed information of Naxagolide, the solubility of Naxagolide in water, the solubility of Naxagolide in DMSO, the solubility of Naxagolide in PBS buffer, the animal experiment (test) of Naxagolide, the cell expriment (test) of Naxagolide, the in vivo, in vitro and clinical trial test of Naxagolide, the EC50, IC50,and Affinity of Naxagolide, Please contact DC Chemicals..

Nitenpyram is a chemical frequently used as an insecticide in agriculture and veterinary medicine. The compound is an insect neurotoxin belonging to the class of neonicotinoids which works by blocking neural signaling of the central nervous system.

For the detailed information of NSC157100, the solubility of NSC157100 in water, the solubility of NSC157100 in DMSO, the solubility of NSC157100 in PBS buffer, the animal experiment (test) of NSC157100, the cell expriment (test) of NSC157100, the in vivo, in vitro and clinical trial test of NSC157100, the EC50, IC50,and Affinity of NSC157100, Please contact DC Chemicals..

For the detailed information of NSC17711, the solubility of NSC17711 in water, the solubility of NSC17711 in DMSO, the solubility of NSC17711 in PBS buffer, the animal experiment (test) of NSC17711, the cell expriment (test) of NSC17711, the in vivo, in vitro and clinical trial test of NSC17711, the EC50, IC50,and Affinity of NSC17711, Please contact DC Chemicals..

For the detailed information of Ospemifene, the solubility of Ospemifene in water, the solubility of Ospemifene in DMSO, the solubility of Ospemifene in PBS buffer, the animal experiment (test) of Ospemifene, the cell expriment (test) of Ospemifene, the in vivo, in vitro and clinical trial test of Ospemifene, the EC50, IC50,and Affinity of Ospemifene, Please contact DC Chemicals..

For the detailed information of PB30239, the solubility of PB30239 in water, the solubility of PB30239 in DMSO, the solubility of PB30239 in PBS buffer, the animal experiment (test) of PB30239, the cell expriment (test) of PB30239, the in vivo, in vitro and clinical trial test of PB30239, the EC50, IC50,and Affinity of PB30239, Please contact DC Chemicals..

For the detailed information of Phenothrin, the solubility of Phenothrin in water, the solubility of Phenothrin in DMSO, the solubility of Phenothrin in PBS buffer, the animal experiment (test) of Phenothrin, the cell expriment (test) of Phenothrin, the in vivo, in vitro and clinical trial test of Phenothrin, the EC50, IC50,and affinity,of Phenothrin, For the detailed information of Phenothrin, the solubility of Phenothrin in water, the solubility of Phenothrin in DMSO, the solubility of Phenothrin in PBS buffer, the animal experiment (test) of Phenothrin, the cell expriment (test) of Phenothrin, the in vivo, in vitro and clinical trial test of Phenothrin, the EC50, IC50,and affinity,of Phenothrin, Please contact DC Chemicals..

For the detailed information of PST2286, the solubility of PST2286 in water, the solubility of PST2286 in DMSO, the solubility of PST2286 in PBS buffer, the animal experiment (test) of PST2286, the cell expriment (test) of PST2286, the in vivo, in vitro and clinical trial test of PST2286, the EC50, IC50,and affinity,of PST2286, Please contact DC Chemicals..

For the detailed information of RO 15-3890, the solubility of RO 15-3890 in water, the solubility of RO 15-3890 in DMSO, the solubility of RO 15-3890 in PBS buffer, the animal experiment (test) of RO 15-3890, the cell expriment (test) of RO 15-3890, the in vivo, in vitro and clinical trial test of RO 15-3890, the EC50, IC50,and Affinity of RO 15-3890, Please contact DC Chemicals..

A small molecule tumor translocation inhibitor that inhibits the prostate cancer cell transcriptional program, in part by inhibition of the demethylase KDM4C (IC50=30 uM).

For the detailed information of SKP2-C25, the solubility of SKP2-C25 in water, the solubility of SKP2-C25 in DMSO, the solubility of SKP2-C25 in PBS buffer, the animal experiment (test) of SKP2-C25, the cell expriment (test) of SKP2-C25, the in vivo, in vitro and clinical trial test of SKP2-C25, the EC50, IC50,and affinity,of SKP2-C25, For the detailed information of SKP2-C25, the solubility of SKP2-C25 in water, the solubility of SKP2-C25 in DMSO, the solubility of SKP2-C25 in PBS buffer, the animal experiment (test) of SKP2-C25, the cell expriment (test) of SKP2-C25, the in vivo, in vitro and clinical trial test of SKP2-C25, the EC50, IC50,and affinity,of SKP2-C25, Please contact DC Chemicals..

For the detailed information of SR03168, the solubility of SR03168 in water, the solubility of SR03168 in DMSO, the solubility of SR03168 in PBS buffer, the animal experiment (test) of SR03168, the cell expriment (test) of SR03168, the in vivo, in vitro and clinical trial test of SR03168, the EC50, IC50,and Affinity of SR03168, Please contact DC Chemicals..

For the detailed information of SR03298A, the solubility of SR03298A in water, the solubility of SR03298A in DMSO, the solubility of SR03298A in PBS buffer, the animal experiment (test) of SR03298A, the cell expriment (test) of SR03298A, the in vivo, in vitro and clinical trial test of SR03298A, the EC50, IC50,and Affinity of SR03298A, Please contact DC Chemicals..

For the detailed information of SR10067, the solubility of SR10067 in water, the solubility of SR10067 in DMSO, the solubility of SR10067 in PBS buffer, the animal experiment (test) of SR10067, the cell expriment (test) of SR10067, the in vivo, in vitro and clinical trial test of SR10067, the EC50, IC50,and affinity,of SR10067, For the detailed information of SR10067, the solubility of SR10067 in water, the solubility of SR10067 in DMSO, the solubility of SR10067 in PBS buffer, the animal experiment (test) of SR10067, the cell expriment (test) of SR10067, the in vivo, in vitro and clinical trial test of SR10067, the EC50, IC50,and affinity,of SR10067, Please contact DC Chemicals..

For the detailed information of Tenovin-5, the solubility of Tenovin-5 in water, the solubility of Tenovin-5 in DMSO, the solubility of Tenovin-5 in PBS buffer, the animal experiment (test) of Tenovin-5, the cell expriment (test) of Tenovin-5, the in vivo, in vitro and clinical trial test of Tenovin-5, the EC50, IC50,and affinity,of Tenovin-5, Please contact DC Chemicals..

For the detailed information of Tradipitant(VLY-686), the solubility of Tradipitant(VLY-686) in water, the solubility of Tradipitant(VLY-686) in DMSO, the solubility of Tradipitant(VLY-686) in PBS buffer, the animal experiment (test) of Tradipitant(VLY-686), the cell expriment (test) of Tradipitant(VLY-686), the in vivo, in vitro and clinical trial test of Tradipitant(VLY-686), the EC50, IC50,and affinity,of Tradipitant(VLY-686), For the detailed information of Tradipitant(VLY-686), the solubility of Tradipitant(VLY-686) in water, the solubility of Tradipitant(VLY-686) in DMSO, the solubility of Tradipitant(VLY-686) in PBS buffer, the animal experiment (test) of Tradipitant(VLY-686), the cell expriment (test) of Tradipitant(VLY-686), the in vivo, in vitro and clinical trial test of Tradipitant(VLY-686), the EC50, IC50,and affinity,of Tradipitant(VLY-686), Please contact DC Chemicals..

For the detailed information of Vonoprazan, the solubility of Vonoprazan in water, the solubility of Vonoprazan in DMSO, the solubility of Vonoprazan in PBS buffer, the animal experiment (test) of Vonoprazan, the cell expriment (test) of Vonoprazan, the in vivo, in vitro and clinical trial test of Vonoprazan, the EC50, IC50,and affinity,of Vonoprazan, For the detailed information of Vonoprazan, the solubility of Vonoprazan in water, the solubility of Vonoprazan in DMSO, the solubility of Vonoprazan in PBS buffer, the animal experiment (test) of Vonoprazan, the cell expriment (test) of Vonoprazan, the in vivo, in vitro and clinical trial test of Vonoprazan, the EC50, IC50,and affinity,of Vonoprazan, Please contact DC Chemicals..

For the detailed information of VRT-1353385, the solubility of VRT-1353385 in water, the solubility of VRT-1353385 in DMSO, the solubility of VRT-1353385 in PBS buffer, the animal experiment (test) of VRT-1353385, the cell expriment (test) of VRT-1353385, the in vivo, in vitro and clinical trial test of VRT-1353385, the EC50, IC50,and affinity,of VRT-1353385, For the detailed information of VRT-1353385, the solubility of VRT-1353385 in water, the solubility of VRT-1353385 in DMSO, the solubility of VRT-1353385 in PBS buffer, the animal experiment (test) of VRT-1353385, the cell expriment (test) of VRT-1353385, the in vivo, in vitro and clinical trial test of VRT-1353385, the EC50, IC50,and affinity,of VRT-1353385, Please contact DC Chemicals..

For the detailed information of Zucapsaicin, the solubility of Zucapsaicin in water, the solubility of Zucapsaicin in DMSO, the solubility of Zucapsaicin in PBS buffer, the animal experiment (test) of Zucapsaicin, the cell expriment (test) of Zucapsaicin, the in vivo, in vitro and clinical trial test of Zucapsaicin, the EC50, IC50,and affinity,of Zucapsaicin, For the detailed information of Zucapsaicin, the solubility of Zucapsaicin in water, the solubility of Zucapsaicin in DMSO, the solubility of Zucapsaicin in PBS buffer, the animal experiment (test) of Zucapsaicin, the cell expriment (test) of Zucapsaicin, the in vivo, in vitro and clinical trial test of Zucapsaicin, the EC50, IC50,and affinity,of Zucapsaicin, Please contact DC Chemicals..

Foretinib (GSK1363089; XL880; EXEL-2880; GSK089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR.

Forsythoside B is a phenylethanoid glycoside isolated from the leaves of Lamiophlomis rotata Kudo, a Chinese folk medicinal plant for treating inflammatory diseases and promoting blood circulation.

Fosbretabulin disodium(CA 4DP; CA 4P) is a microtubule destabilizing drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.

Fosdagrocorat (PF 04171327) is an orally available, potential dissociated agonist of the glucocorticoid receptor (GR) for the treatment of rheumatoid arthritis, the phosphate ester prodrug of PF-00251802 (dagrocorat)..

Fosfluconazole (INN) is a water-soluble phosphate prodrug of fluconazole

Foslinanib (TRX-818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation.

Fosmidomycin sodium salt is a phosphonic acid antibiotic and a antimalarial drug, which is active against both Gram-negative and Gram-positive bacteria.

Fosravuconazole is a prodrug of ravuconazole, with antifungal activity.

Fostamatinib (R788) is a prodrug of the active metabolite R406, which is a potent, ATP-competitive inhibitor of Syk kinase with Ki/IC50 of 30/41 nM.

Fosteabine is an oral and prodrug analogue of cytarabine which is resistant to deoxycytidine deaminase.

Foxy-5 is a novel Wnt-5A mimicking hexapeptide that inhibits breast cancer metastasis in vivo by targeting cell motility.

FPL64176 is a potent L-type Ca++ channel activator with EC50 of 16 nM.

FQI1 is a small-molecule inhibitor of transcription factor LSF with IC50 of 2.1 uM.

FQI2 is a small-molecule inhibitor of transcription factor LSF with IC50 of 0.71 uM.

FR 900098 is a derivative of fosmidomycin that inhibits DOXP reductoisomerase, demonstrates antimalarial activity with IC50 of 170, 170, and 90 nM for HB3, A2, and Dd2 P. falciparum strains, respectively..

FR194738 is a squalene epoxidase inhibitor. FR194738 inhibits squalene epoxidase activity in HepG2 cell homogenates with an IC50 of 9.8 nM.

FR58P1a is a mitochondrial metabolism-affecting compound that uncouples OXPHOS through a protonophoric mechanism, selectively inhibits migration in triple-negative breast cancer cells via Sirt1/AMPK/β1-integrin pathway.

FR-901464 is a potent antitumor natural product that binds to the splicing factor 3b (SF3b) complex and inhibits pre-mRNA splicing, inhibits cell cycle progression at G1 and G2/M phases..

Framycetin (Fradiomycin B; Neomycin B) is an aminoglycoside antibiotic. It inhibits hammerhead ribozyme with a Ki of 13.5 μM.

Framycetin sulphate

FRAX1036 is a novel ATP-competitive small molecule inhibitor of group I p21-activated Kinases (PAKs).

FRAX486 is a selective inhibitor of group I PAKs with IC50s of 8.25/39.5, /55.3 nM for PAK1/PAK2/PAK3 respectivelt; less potent for PAK4(IC50=779 nM).

Frentizole, an FDA-approved immunosuppressive drug, is a novel inhibitor of the Aβ-ABAD interaction.

Frovatriptan Succinate is the succinate salt form of frovatriptan, a synthetic triptan with serotonin (5-HT) receptor agonist activity especially for the 5-HT1B/1D receptors.

FSC 231 (FSC231) is the first, cell-permeable small-molecule inhibitor of PICK1 PDZ domain with Kd of 10.1 uM.

FT-001 is a novel potent, orally acitve inhibitor of BET bromodomain with IC50 of 0.1 uM for BRD4 BD1.

FT-671 is a novel potent, specific, non-covalent USP7 inhibitor with Kd of 65 nM (USP7 catalytic domain).

FT895 (FT-895) is a potent and selective inhibitor of HDAC11 with IC50 of 3 nM, displays no significant activity against HDAC1-10 (IC50>5 uM).

FTBMT is a novel selective GPR52 agonist of GPR52, increases intracellular cAMP levels in CHO cells expressing human, mouse, or rat GPR52, with pEC50 of 7.03, 6.85, and 6.87M, respectively.

FTI 277 HCl is the methyl ester of FTI 277, which is a potent and selective farnesyltransferase (FTase) inhibitor with IC50 of 500 pM, about 100-fold selectivity over the closely related GGTase I.

FtsZ inhibitor C109 (Compound 10126109) is a broad spectrum antibacterial compound that inhibits the cell division protein FtsZ, inhibits the FtsZ GTPase activity with IC50 of 8.2 uM.

FTY720 (Fingolimod, Gilenya) is a S1P antagonist with IC50 of 0.033 nM.

Fuchsine base (monohydrochloride) is a magenta dye, which is certified for use for acid-fast staining with carbol-fuchsin.

Fumosorinone is a novel potent, selective protein tyrosine phosphatase SHP2 inhibitor with IC50 of 6.31 uM.

Furamidine dihydrochloride (NSC 305831) tyrosyl-DNA phosphodiesterase (Tdp1), also is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with IC50 of 9.4 uM.

Fusidate Sodium is a sodium salt form of fusidic acid, a bacteriostatic antibiotic derived from the fungus Fusidium coccineum and used as a topical medication to treat skin infections.

FV-100 (Valnivudine, CF-1743) is a potent, selective, bicyclic nucleoside analogue inhibitor of varicella zoster virus (VZV) with EC50 of subnanomolar range in vitro..

FzM1.8 is a small molecule, allosteric agonist of the Frizzled receptor Fzd4 with pEC50 of 6.4, potentiates β-catenin pathway in the absence of any WNT ligand.

G 0507 is a novel inhibitor of the bacterial LolCDE ABC transporter, binds to LolCDE and stimulates its ATPase activity.

G 573 is a potent and selective, allosteric inhibitor of MEK with Ki of 0.3 nM.

G0775 is a Synethetic analogs of arylomycins.

G10 (STING Agonist 1) is a novel human-specific STING agonist.

G3-C12 (TFA) is a galectin-3 binding peptide, with high affinity (Kd) of 88 nM, but shows no affinity for other galectin family members or to other lectins.

G-5555 is a potent and selective PAK1 inhibitor (Ki=3.7 nM).

G6PD activator AG1 (AG1) is a specific, small molecule that increases the activity of the wild-type, Canton mutant (R459L, EC50=3 uM) and several other common G6PD mutants; displays no effect on the dimerization or activity of several other NAD- or NADP+-dependent dimeric or tetrameric enzymes, including 6PGD, GAPDH, ALDH2, and ALDH3A1; attenuates ROS-induced pericardial edema in a G6PD-dependent manner in zebrafish, reduces hemolysis of human erythrocytes

G-744 is a highly potent, selective inhibitor of BTK with biochemical Ki of 1.28 nM.

G907 is a potent, selective small-molecule antagonist of ATP-binding cassette (ABC) transporter MsbA with IC50 of 18 nM.

G9a inhibitor E72 (E-72) is a potent inhibitor of histone H3K9 methyltransferases G9a and G9a-like protein (GLP) with Kd of 136 nM and 164 nM, shows selectivity over the related H3K9 methyltransferase Suv39H2.

Gabapentin (Neurontin) is a pharmaceutical drug, specifically a GABA analog.

GAK inhibitor 49 is a potent, selective, ATP-competitive inhibitor of cyclin G-associated kinase (GAK, cell IC50=56 nM) with favourable NAK family selectivity (AAK1, STK16, BMP2K).

Galactose 1-phosphate is an intermediate in the galactose metabolism and nucleotide sugars.

Galactose 1-phosphate Potassium salt is is an intermediate in the galactose metabolism and nucleotide sugars

Galvestine-1 is a small molecule MGDG (monogalactosyldiacylglycerol) synthase inhibitor with IC50 of 10 uM by competing with diacylglycerol binding.

Gambogenic acid (GNA) is a polyprenylated xanthone isolated from gamboge, shows potent antitumor activity and can effectively inhibit the survival and proliferation of cancer cells.

Gamitrinib TPP is a GA mitochondrial matrix inhibitor.

gamma-secretase modulator 3 is a gamma-secretase modulator.

Ganaplacide (KAF156, GNF-156) is a novel antimalarial clinical candidate that shows blood schizonticidal activity with IC50 of 6-17.4 nM against P falciparum drug-sensitive and drug-resistant strains.

GANT 58 is a novel and potent Gli antagonist that inhibits GLI1-induced transcription (IC50 = 5 uM).

GAPDS is a small molecule that targets the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Garcinol (Camboginol) is a potent, natural inhibitor of histone acetyltransferases (HATs) p300 (IC50=7 uM) and PCAF (IC50=5 uM) both in vitro and in vivo.

Gardiquimod trifluoroacetate is a specific TLR7 agonist which can also inhibit HIV-1 reverse transcriptase.

Garenoxacin is a quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.

Garenoxacin mesylate hydrate is a novel oral des-fluoro(6) quinolone with potent antimicrobial activity, against common respiratory pathogens, including resistant strains.

GAT-100 (GAT100) is a potent, selective CB1R negative allosteric modulator (NAM) with cAMP EC50 and β-arr EC50 of 174 nM and 2.1 nM, does not exhibit inverse agonism.

GAT-211 (GAT211) is a selective cannabinoid 1 receptor (CB1R) positive allosteric modulator with pKb of 7.26, Arrestin2 EC50 of 775 nM.

GB-110 is a potent, non-peptidic agonist of PAR2 that selectively induces PAR2-mediated intracellular Ca(2+) release in HT29 cells with EC50 of 0.28 uM.

GB1107 (GB-1107, GB 1107) is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with Kd of 37 nM (human Galectin-3).

GB-83 is a selective, reversible PAR2 (Protease-activated receptor 2) antagonist with IC50 of 2 uM.

GB-88 is a selective, orally available PAR2 antagonist that inhibits PAR2 activated Ca(2+) release with IC50 of 2 uM.

GDC-0077 is an orally available PI3K inhibitor with potential antineoplastic activity. GDC-0077 is extracted from patent WO 2017001645 A1, formula I.

GDC-0326 is a potent and selective inhibitor of α-Isoform of Phosphoinositide 3-Kinase (PI3Kalpha inhibitor).

GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM; >700-fold selectivity over PI3Kα and other 266 kinases.

GDC046 is a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile.

GDC-0623 is a potent, ATP-uncompetitive inhibitors of MEK1(Ki=0.13 nM, +ATP).

GDC-0853 is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.

GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer..

GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer..

GDC-0927 Racemate is a degrader of estrogen receptor, potently inhibits ER-α activity, with an IC50 of 0.2 nM, and is used in the research of ER-related diseases.

GDC-0941 2 MeSO3H salt is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

GDC-0994 is a potent, orally available ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.

GeA-69(GeA69) is a potent, selective, allosteric, cell-active PARP14 macrodomain 2 (MD2) inhibitor with Kd of 0.86 uM in ITC assays.

Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.

Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP.

Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP.

Gemcitabine elaidate is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.

Gemcitabine Hydrochloride (Gemzar) is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively,showed potent activity against COVID-19(SARS-COV-2) with EC50 MERS-COV(1.216), SARS-COV(4.9

Gemcitabine(Gemzar) belongs to the group of medicines called antimetabolites.

Gemifloxacin mesylate (trade name Factive, Oscient Pharmaceuticals) is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia.

Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors (CysLT1 and CysLT2) antagonist, with IC50s of 1.7, 25 nM for human CysLT1 and CysLT2, respectively.

Genz-644282 is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity(IC50=1.2 nM).

Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor.

Geraniin is a TNF-α releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC50 of 43 μM.

Gerfelin is an osteoclastogenesis inhibitor (IC50=61 uM) through the competitive inhibition of glyoxalase I (GLO1) with Ki of 0.15 uM.

Gestodene(SHB 331;WL 70) is a progestogen hormonal contraceptive.

Gestrinone (R2323) is a synthetic steroid hormone used to treat endometriosis. It inhibits leiomyoma cells with an IC50 of 43.67 μM.

GGTI 2417 is the methyl ester prodrug of GGTI-2418, a highly potent, competitive, and selective inhibitor of GGTase I.

GGTI 2418 sodium (PTX 100) is a highly potent, competitive, and selective peptidomimetic inhibitor of geranylgeranyltransferase I (GGTI) with IC50 of 9.5 nM, displays 5,600-fold selectivity over FTase.

GGTI-2133 is a potent and selective GGTase I inhibitor

GGTI-2147 is a non-thiol peptidomimetic that inhibits GGTase I and blocks geranyl-geranylation of Rap1A (IC50=0.5 uM).

GGTI-286 is a CAAX peptidomimetic that is a potent, cell-permeable, and selective inhibitor of GGTase I with IC50 of 2 uM, 25-fold more potent than FTI-277.

GGTI-286 is a CAAX peptidomimetic, potent, cell-permeable, and selective inhibitor of GGTase I with IC50 of 2 uM, 25-fold more potent than FTI-277.

GGTI-DU40 is highly selective inhibitor for GGTase-I both in vitro and in living cells. Studies indicate GGTI-DU40 blocks prenylation of a number of geranylgeranylated CaaX proteins. Treatment of MDA-MB-231 breast cancer cells with GGTI-DU40 inhibited thr

Ghrelin agonist HM01 is a novel potent, orally available ghrelin (GHS-R) agonist with Ki of 1.42 nM (human GHS-R1a), induces potent activation of intracellular calcium signaling with EC50 of 1.25 nM.

GHRP-2 is a synthetic hexapeptide Growth Hormone Releasing Peptide (GHRP), which acts on the hypothalamus and the pituitary gland to release growth hormone with a slight stimulator effect on Prolactin, ACTH and Cortisol levels.

GI-530159 (ICA-069771) is a novel potent, selective, mechano-sensitive K2P channel (TERK) opener with EC50 of 1 uM for TERK1.

Givinostat (ITF2357) is a potent HDAC inhibitor for maize HD2, HD1B and HD1A with IC50 of 10 nM, 7.5 nM and 16 nM. Phase 1/2.

GK563 (GK-563) is a potent, selective inhibitor of Ca2+-independent phospholipase A2 (GVIA iPLA2) with IC50 of 1 nM, >20,000-fold selectivity over GIVA cPLA2.

GKI-1 is a Greatwall (GWL) kinase inhibitor with IC50s of 4.9 and 2.5 µM against hGWLFL and hGWL-KinDom, respectively. GKI-1 robustly inhibits ROCK1 with an IC50 of 11 µM, but only weakly affected PKA.

GL-1196 is a PAK4 inhibitor that effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclinD1 pathway and CDK4/6 expression.

Glabrescione B (GlaB) is a small molecule binding to Gli1 zinc finger and impairing Gli1 activity by interfering with Gli1/DNA interaction, inhibits Hh signaling by impairing Gli1 function; inhibits the growth of Hedgehog-dependent tumor cells in vitro and in vivo, inhibits Gli1-dependent growth of cerebellum-derived normal progenitors; inhibits the growth of Gli-dependent medulloblastoma and tumor-derived stem-like cells; inhibits the growth of Gli-dependent basal cell carcinoma in vitro and in vivo.

Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase..

Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase..

Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. Gln-AMS inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 µM.

Gln-AMS is an aminoacyl-tRNA synthetases (AARS) inhibitor, which binds the A-domain within the NRPS enzymes.

GLP-1 receptor agonist-1 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.

GLP-1(7-36) is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM.

GLPG 0974 is a potent, selective free fatty acid receptor 2 (FFA2, GPR43) antagonist with IC50 of 95 nM.

GLPG-2222 (ABBV-2222, Galicaftor) is a novel potent and efficacious CFTR corrector with EC50 of 5 nM.

GLS1 inhibitor is an inhibitor of glutaminase 1

GLS4 (Morphothiadin) is a potent inhibitor of HBV capsid assembly, inhibits HBV replication (EC50=62.24 nM) and reduces HBV-DNA levels in HepG.2.2.15 cells (IC50=14 nM), shows efficacy against ADV-resistant HBV mutations.

Glucokinase activator 1 is a liver-directed glucokinase activator with an EC50 of 34 nM.

Glumetinib (SCC 244) is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM.

Glycodeoxycholate Sodium is a bile salt.

Glycodeoxycholic acid monohydrate is a nuclear receptor ligand.

Glycogen is a glycolytic intermediates and high-energy phosphates that can serve as a form of energy storage in humans, animals, fungi, and bacteria.

Glycopyrronium bromide (CHF 5259) is a peripherally-acting quaternary ammonium antimuscarinic agent with little or no central nervous system activity.

GlyT1 inhibitor 46 is a novel potent, selective, orally available inhibitor of glycine transporter-1 (GlyT1) with IC50 of 38 and 21 nM for rat and human GlyT1, respectively.

Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders.

GMI-1070 (Rivipansel, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively.

GNA002 (GNA-002) is a gambogenic acid (GNA) derivative that specifically and covalently binds to Cys668 within the EZH2-SET domain, trigges EZH2 degradation (IC50=1.1 uM) through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination.

GNE 220 (Hydrochloride) is a potent and selective inhibitor of MAP4K4, with an IC50 of 7 nM.

GNE-0439 is a novel potent, selective inhibitor of Nav1.7 channel with IC50 of 0.34 uM, shows high selectivity over Nav1.5 (IC50=38.3 uM).

GNE-049 (GNE049) is a potent, selective, orally available inhibitor of CBP/p300 bromodomain with biochemical IC50 of 1.1/2.3 nM, respectively.

GNE-220 is a potent and selective inhibitor of MAP4K4 with IC50 of 7 nM, also inhibits MINK (MAP4K6), DMPK and KHS1 (MAP4K5) with IC50 of 9 nM, 476 nM and 1,110 nM.

GNE-272 is a in Vivo Probe for the Bromodomains of CBP/EP300.

GNE-2861 is a potent, selective group II PAK (PAK4/5/6) inhibitor with IC50 of 7.5/126/36 nM, respectively, shows selectivity over group I PAKs (IC50=5.42/0.97/>10 uM for PAK1/2/3).

GNE-293 is a potent and selective PI3Kδ inhibitor with Ki of 0.47 nM, displays 256, 420, 219-fold selectivity over PI3Kα, PI3Kβ, PI3Kγ, respectively.

GNE-3500 (GNE3500) is a potent, selective, and orally bioavailable RORγ inhibitor with IC50 of 47 nM in IL-17 promoter assays.

GNE-371 is a potent and selective chemical probe for the second bromodomains of human transcription-initiation-factor TFIID subunit 1 and transcription-initiation-factor TFIID subunit 1-like, with an IC50 of 10 nM for TAF1(2).

GNE-375 is a potent, selective BRD9 inhibitor with IC50 of 5 nM, displays >480-fold selectivity over BRD4, CECR2, and TAF1.

GNE-431 is a potent, selective and noncovalent Btk inhibitor with IC50 of 3.2 nM and 2.5 nM for WT Btk and C481S mutant, respectively.

GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with IC50 of 4 nM for PI3Kα, Kiapp is 21 nM for mTOR.

GNE-490 is a highly selective pan-PI3K inhibitor and demonstrates selectivity over mTOR.

GNE-493 is a potent, selective, and orally available dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/12/16/16/32 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR respectively.

GNE-6468 (GNE6468) is a potent and selective RORc inverse agonist (EC50=2 nM) with >1,000-fold selectivity for RORc over PPARγ.

GNE-6776 is a novel potent, specific, non-covalent, orally bioavailable USP7 inhibitor with IC50 of 1.34 uM .

GNE-781 is a potent, selective, non-CNS penetrant, orally active CBP/p300 bromodomain inhibitor with IC50 of 0.94/1.2 nM in TR-FRET assays.

GNE-7915 tosylate (GNE7915 tosylate) is a highly potent, selective, and brain-penetrable LRRK2 inhibitor with IC50 of 1.9 nM.

GNE-8324 is a potent and selective NMDA receptor PAM.

GNE-886 is a potent and selective CECR2 bromodomain inhibitor with IC50 of 16 nM.

GNE-900 (GNE900) is a potent, selective, ATP-competitive, and orally bioavailable Chk1 inhibitor with IC50 of <1 nM.

GNE-955 is a potent pan Pim kinase inhibitor with Kis of 18, 110, 8 nM for Pim1, Pim2, Pim3, respectively.

GNF-6231 is a potent, orally active and selective Porcupine inhibitor with IC50 of 0.8 nM.

GNF-7 is a potent type-II kinase Bcr-Abl inhibitor with IC50 of <5 nM, 61 nM, 122 nM, 136 nM, and 133 nM for M351T, T315I, E255 V, G250E, and c-Abl, respectively.

GNX-865 is a potent mitochondrial permeability transition pore (mPTP) inhibitor with EC50 of 105 uM (mitochondrial swelling).

GO289 (GO-289, GO 289) is a potent and selective inhibitor of casein kinase 2 (CK2) with IC50 of 7 nM in in vitro kinase assays, shows minor effects on CKIδ and CKIα activity in vitro.

Golgicide A is a potent, highly specific, reversible inhibitor of the cis-Golgi ArfGEF GBF1, inhibits the effect of shiga toxin on protein synthesis with IC50 of 3.3 uM.

GOT1 inhibitor 2c is a first-in-class, non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with IC50 of 8.2 uM..

GPDA(Glycylproline p-nitroanilide tosylate) is the substarate of X-Prolyl dipeptidyl-aminopeptidase in the enzyme assay.

GPR139 agonist AC4 is a novel small molecule GPR139 receptor agonist with EC50 of 220 nM in calcium mobilization assay in CHO-GPR139 cells. .

GPR39 modulator 3 is a Hedgehog pathway inhibitor that has high cellular potency (EC50=5 nM) in the reporter gene assay, activates the orphan receptor GPR39 and potently reduces of Gli1 and Ptch1 mRNA levels.

GPR39 modulator 7 is a Hedgehog pathway inhibitor that has high cellular potency (EC50=20 nM) in the reporter gene assay, activates the orphan receptor GPR39 and potently reduces of Gli1 and Ptch1 mRNA levels.

GPR4 antagonist 3 is a selective, and orally available GPR4 antagonist with an IC50 of 70 nM. Anti-inflammatory activities.

GPR40 AgoPAM AP5 is a potent, selective GPR40 AgoPAM (full agonist with positive allosteric modulation) with hIP1 EC50 of 0.8 nM, high selectivity over the GPR120 receptor (EC50>30 uM).

Gpr52 antagonist E7 (Scabertopin) is a novel Gpr52-specific small molecule antagonist, reduces mutant HTT levels and rescues Huntington's disease-associated phenotypes in cellular and mouse models..

GR-127935 potent and selective 5-HT1B/1D receptor antagonist with pKi of 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptor.

GR148672X is a specific TGH inhibitor.

GR-64349 is a potent and selective tachykinin NK2 receptor agonist with EC50 of 3.7 nM, displays >1000- and >300-fold selectivity over NK1 and NK3 receptors, respectively..

GR-73632 is a potent and selective tachykinin NK1 receptor agonist with EC50 of 2 nM, promotes differentiation but not survival of rat chromaffin cells in vitro..